Shots:
- ViVerita Therapeutics & BI have entered into a strategic research collaboration to accelerate discovery & validation of novel cancer targets. Although financial terms of the deal were not disclosed
- As per the deal, ViVerita will utilize its in vivo CRISPR discovery platform to study selected potential targets from BI, evaluating their functions in physiologically relevant environment
- ViVerita’s in vivo CRISPR discovery platform integrates advanced in vivo genetic screening with accurate disease models to identify hard-to-target cancer pathway drivers & validate external targets under physiological conditions
Ref:Â PRNewswire |Â Image:Â ViVerita Therapeutics and Boehringer Ingelheim
Related News:-Â Boehringer Ingelheim Enters a ~$573M Deal with Tessellate Bio to Develop Novel Therapies for ALT-positive tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
